OBJECTIVE To evaluate the efficacy and safety of artificial pancreas treatment in non-pregnant outpatients with type 1 diabetes.
Introduction
Despite substantial advances in the treatment of type 1 diabetes, maintaining good glycaemic control without hypoglycaemia remains a challenge for patients at all ages and for healthcare providers. Currently, insulin treatment strategies in type 1 diabetes include either multiple daily insulin injections or continuous subcutaneous insulin infusion with an insulin pump. In 2008, the National Institute for Health and Care Excellence concluded that continuous subcutaneous insulin infusion has a favourable effect on glycated haemoglobin (HbA 1c ) and incidence of hypoglycaemia in patients with type 1 diabetes. 1 Moreover, a metaanalysis of 19 trials concluded that continuous subcutaneous insulin infusion had a favourable effect on glycaemic control in adults with type 1 diabetes compared with multiple daily insulin injections. 2 In addition, in a recent cluster randomised controlled trial, patients with type 1 diabetes who used continuous subcutaneous insulin infusion instead of multiple daily insulin injections reported additional benefits in quality of life and greater treatment satisfaction. 3 Until recently, continuous subcutaneous insulin infusion was mostly guided by self-monitoring of capillary glucose testing. 4 However, insulin pumps are now also used in conjunction with real time continuous glucose monitoring, hence allowing the doi: 10.1136/bmj.k1310 | BMJ 2018;361:k1310 | the bmj patient to manually modify the insulin infusion rate according to continuous glucose monitoring values (known as sensor augmented pump treatment). 4 5 The recent introduction of a low glucose suspend feature has allowed for automatic pump suspension when a preprogrammed threshold value of continuous glucose monitoring is reached. 6 Based on a 2016 analysis, the use of sensor augmented pump treatment and the low glucose suspend feature was found to be cost effective compared with continuous subcutaneous insulin infusion and self-monitoring of blood glucose for patients with type 1 diabetes in the United Kingdom. 7 Artificial pancreas treatment, also referred to as closed loop glucose control, is an emerging treatment option combining an insulin pump and continuous glucose monitoring with a control algorithm to deliver insulin in a glucose responsive manner (that is, a single hormone artificial pancreas system). Glucagon can also be delivered in a similar glucose responsive fashion, as accommodated by dual hormone artificial pancreas systems. Therefore, compared with insulin pumps or sensor augmented pumps, artificial pancreas use can reduce the burden for patients by automatically adjusting the amount of insulin entering the body on the basis of sensor glucose levels. Several artificial pancreas systems have been developed, and their safety and efficacy have been evaluated in many studies, showing promising results. An early pooled analysis included only four studies in an inpatient setting, 8 whereas an overview published in 2015 summarised existing data from randomised controlled trials up to September 2014. 9 Finally, a recent metaanalysis summarised evidence from published trials of artificial pancreas systems in outpatients with type 1 diabetes. 10 Notably, the US Food and Drug Administration has recently approved the first artificial pancreas system for use by people with type 1 diabetes over 14 years of age, based on a safety outpatient study. 11 This systematic review and metaanalysis aimed to summarise and critically appraise all existing evidence on the clinical efficacy and safety of artificial pancreas systems for the management of type 1 diabetes in the outpatient setting.
Methods
This systematic review and meta-analysis is based on a prespecified protocol (appendix 1), and is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (appendix 2). 12 Search strategy and selection criteria We searched Medline, Embase, Cochrane Database of Systematic Reviews, and the Central Register of Controlled Trials from inception to 2 February 2018. Our search strategy was based on search terms describing the intervention (artificial pancreas or closed loop system) in addition to a filter for randomised trials. We omitted terms related to type 1 diabetes to avoid missing potentially relevant studies. 13 14 We used search terms that had been identified from initial scoping searches, target references, and browsing of database thesauruses (web appendix 3). We imposed no restrictions based on language or publication status, searched ClinicalTrials.gov, and sought for additional studies from snowballing of included records.
We included randomised controlled trials in nonpregnant adults, children, and adolescents with type 1 diabetes in the outpatient setting (including hotels, diabetes camps, or normal living conditions), irrespective of trial design (parallel or crossover) or duration of intervention, which compared artificial pancreas systems with any type of insulin based treatment. Such comparative treatments included multiple daily insulin injections, insulin pump treatment without continuous glucose monitoring or with blinded continuous glucoses monitoring, and sensor augmented pumps with or without a low glucose suspend feature.
Data extraction
References identified were imported into a reference management software (Endnote, Clarivate Analytics) for deduplication. Potentially eligible records were exported to Covidence (Covidence, Veritas Health Innovation) for screening. Three reviewers (EB, EA, and KK) working independently, screened all records in duplicate, and disagreements were arbitrated by a senior team member (AT). Initially, records were screened at title and abstract level, and potentially eligible studies were assessed in full text.
If multiple records of one study were retrieved, we collated data from all records, and used data from the report with the longest duration of follow-up. We extracted data for study and participant baseline characteristics, interventions, comparators, and clinical outcomes in duplicate (EB, EA, and TK) by using an electronic, pilot tested, data extraction form (web appendix 4). Disagreements were resolved by consensus or following discussion with a senior reviewer (AT).
Outcomes
The primary outcome was proportion (%) of time when the sensor glucose level was within the near normoglycaemic range (3.9-10 mmol/L). Secondary outcomes included proportion (%) of time when the sensor glucose level was above 10 mmol/L or below 3.9 mmol/L, incidence of severe hypoglycaemia, mean sensor glucose level, total daily insulin needs, and glycated haemoglobin (HbA 1c ). We also used low blood glucose index overnight as an additional outcome to assess hypoglycaemia. Low blood glucose index is a weighted average of the number of hypoglycaemic readings with progressively increasing weights as glucose levels decrease and is associated with the risk of hypoglycaemia and prediction of severe hypoglycaemic episodes. 15 When available, for proportion (%) of time in the near normoglycaemic range, hyperglycaemia (>10 mmol/L), or hypoglycaemia (<3.9 mmol/L), we extracted data both for 24 hour and overnight periods (as defined in each individual study).
Statistical analysis
We conducted meta-analyses when data were available for at least two studies. We calculated weighted mean differences with 95% confidence intervals, applying an inverse variance weighted random effects model using the DerSimonian and Laird estimation method. 16 We also calculated 95% prediction intervals to estimate a predicted range for the true treatment effect in any one individual study. 17 In addition, to account for uncertainty related to heterogeneity estimates, we calculated 95% confidence intervals applying the Hartung Knapp correction method. 18 For trials reporting only medians and interquartile ranges, we retrieved mean and variance values from authors of original reports or used appropriate formulas to calculate mean and variance, making no assumption on the distribution of the underlying data. 19 We combined data both from parallel group and crossover studies. Finally, for crossover studies that reported their results as parallel group trials, we used appropriate methods to impute within patient differences. 20 We conducted prespecified subgroup analyses based on the mode of use (overnight or over 24 hours) and type of artificial pancreas system (single or dual hormone). A series of a priori decided sensitivity analyses was conducted for the primary outcome, excluding trials at unclear or high risk of bias, trials recruiting people in diabetes camps, or trials with supervised use of artificial pancreas system. We assessed statistical heterogeneity by the χ 2 based Cochran Q test and the τ 2 and I 2 statistics. For HbA 1c , we synthesised only data from trials with at least eight weeks' duration per intervention. All analyses were undertaken in RevMan 5.3 (Nordic Cochrane Centre) and Stata 13.0 (Stata Corporation).
Assessment of risk of bias in individual studies and across studies
Quality assessment was undertaken in duplicate by two independent reviewers (EB and EA), and disagreements were resolved by consensus or arbitrated by a third reviewer (AT). We used the Cochrane Collaboration risk of bias tool to assess risk of bias for the primary outcome for individual studies. For crossover studies, we also assessed a series of methodological challenges that are related to this specific design (appropriateness of crossover design, carry-over effects, unbiased data). 21 We used results to provide an evaluation of the overall quality of the included studies (appendix 5) to inform a sensitivity analysis including only trials at low overall risk of bias.
We explored risk of bias across studies, both visually using a contour enhanced funnel plot, and formally using Egger's statistical test. 22 23 In case of evidence of small study effects, we used the trim and fill method as a sensitivity analysis, to provide an adjusted estimate of the meta-analysis. 24 
Patient involvement
No patients were involved in definition of the research question or the outcome measures, and interpretation or writing up of results. Data relating to the impact of the intervention on participants' quality of life were not extracted. Where possible, results of this systematic review and meta-analysis will be disseminated to the patient community or individual patients and families through the investigators of this meta-analysis. Figure 1 shows the study selection process. Of 10 054 records retrieved, 85 reports qualified for inclusion in our systematic review. After juxtaposing different reports that referred to the same study, 39 publications describing 41 trials (1042 participants with data for 45 comparisons) were used to inform our systematic review. One trial did not report data for outcomes assessed and was not included in the meta-analysis. 57 Table 1 shows characteristics of the 41 studies included in the systematic review and their participants at baseline. The clear majority of included trials used a crossover design, 25-27 29-35 37-41 43-46 50-58 60-63 whereas only seven trials were of parallel design. 28 36 42 47-49 59 The duration of 36 trials lasted up to four weeks, 25-41 43 45-50 52-62 whereas the remaining five trials lasted from eight to 30 weeks. 42 44 51 63 Seventeen trials recruited children or adolescents, 28 61 63 In 32 trials, a single hormone artificial pancreas system was assessed (mostly versus unblinded treatment using sensor augmented pump). 25 Five trials assessed a dual hormone artificial pancreas system, mainly by comparison with insulin pump treatment (consisting of continuous subcutaneous insulin infusion combined with a blinded system of continuous glucose monitoring). 27 34 55 56 Additionally, four studies evaluated both a single hormone and a dual hormone system against control treatment (as three way crossover trials). 33 38-40 In six studies assessing sensor augmented pump treatment, control treatment comprised a sensor augmented pump combined with an low glucose suspend feature. 31 26 51-53 and six used a Medtronic device. 31 36 48 50 58 59 Most trials used a model predictive control algorithm, 25 27 31 48 50 58 four used a fuzzy logic algorithm, 26 51 52 53 four used a control to range algorithm, 30 32 46 49 and the remainder used other algorithms or did not provide relevant details. 28 Enlite Sensor or a FreeStyle Navigator in the artificial pancreas systems, respectively. Type of sensor for continuous glucose monitoring was not reported in two trials. 26 33 In 41 comparisons, the type of sensor for continuous glucose monitoring was identical between artificial pancreas and control arms, whereas four trials did not report information for type of sensor used in the control arm. 26 30 47 49 In terms of setting, 13 trials were held in a diabetes camp or a guesthouse, 28 55 57-63 Only in a small subset of trials were participants using artificial pancreas unsupervised under normal living conditions 25 26 41 45 60-63 ; the remaining studies either used remote monitoring or did not provide relevant details. Participants' mean age and HbA 1c at baseline ranged from 7.0 to 47.0 years and from 6.9% to 8.6%, respectively.
Results

Characteristics of included studies
Risk of bias assessment results
Risk of bias assessment for the primary outcome is presented in appendices 6 and 7. Only nine studies were at low risk of bias. Most studies were deemed at high risk for bias, because either they reported median values instead of mean values, or reported results that required extensive use of imputation methods to be used in meta-analyses.
Primary outcome
All meta-analysis results are presented as summary effect estimates for artificial pancreas systems versus control treatment. Compared with control treatment, use of artificial pancreas was associated with an increased percentage of time (140 additional minutes) in near normoglycaemia (3.9-10.0 mmol/L) over 24 hours (overall weighted mean difference 9.62% (95% confidence interval 7.54% to 11.7%); I 2 =78%, τ 2 =24.09, 32 studies). This effect was consistent both for trials using artificial pancreas overnight (7.16% (5.73% to 8.58%); 0%, 0.0, seven studies) or over 24 hours (10.79% (7.88% to 13.7%); 81%, 39.21, 25 studies; fig 2) . The confidence interval for the overall effect estimate after applying the Hartung Knapp correction was 7.83% to 12.41%, whereas the 95% prediction interval was −0.63% to 19.87%. Of note, the 95% prediction interval was above zero when the artificial pancreas was used overnight (5.29% to 9.02%), suggesting that artificial pancreas use will be beneficial in at least 95% of the individual study settings when applied overnight. However, the prediction interval contained negative values when applied over 24 hours (−2.52% to 24.1%), and therefore might not be beneficial in some settings.
The favourable effect of artificial pancreas use over control treatment was more evident on the proportion of time in near normoglycaemia overnight (overall weighted mean difference 15.15% (95% confidence interval 12.21% to 18.09%); I 2 =73%, τ 2 =43.48, 31 studies). This effect was consistent when artificial pancreas was used either only overnight (14.25% (11.13% to 17.37%); 63%, 19.39, 14 studies) or over 24 hours (16.44% (10.88% to 22.01%); 78%, 99.63, 17 studies; fig 3) , even when the Hartung Knapp correction was applied (appendix 13). Respective 95% prediction intervals suggested that effect on time in near normoglycaemia overnight would be beneficial in at least 95% of the individual study settings when artificial pancreas was applied overnight (4.04% to 24.45%), but not when applied over 24 hours (−5.68% to 38.56%).
Secondary outcmes
Use of artificial pancreas had a favourable effect on time in hyperglycaemia (glucose concentrations >10 mmol/L) during the entire day. Compared with control treatment, this period was shortened by about two hours (overall weighted mean difference −8.52% (95% confidence interval −11.14% to −5.9%); I 2 =80%, τ 2 =28.98, 22 studies), both in trials using artificial pancreas overnight (−6.0% (−8.4% to −3.6%); 0%, 0.0, three studies) and those using artificial pancreas over 24 hours (−9.08% (−12.23% to −5.93%); 83%, 37.53, 19 studies; fig 4) . Similarly, the time when glucose concentrations were higher than 10.0 mmol/L overnight was also shortened compared with control treatment (−11.12% (−13.8% to −8.44%); 71%, 26.13, 23 studies), both in trials that used artificial pancreas either only overnight (−9.23% (−11.67% to −6.79%); 51%, 8.26, 12 studies) or over 24 hours (−13.86% (−19.83% to −7.9%); 80%, 77.07, 11 studies; appendix 8).
Time when glucose concentrations were lower than 3.9 mmol/L over a 24 hour period was shortened with artificial pancreas use by about 20 minutes (overall weighted mean difference −1.49% (95% confidence interval −1.86% to −1.11%); I 2 =74%, τ 2 =0.59, 29 5) . Results were consistent for overnight time when concentrations were lower than 3.9 mmol/L (−2.22% (−2.78% to −1.65%); 72%, 1.34, 29 studies; appendix 9). Data on incidence of severe hypoglycaemia (that is, hypoglycaemia requiring third party assistance) were available in 27 studies (804 patients). Overall, incidence of severe hypoglycaemia was very low both in groups using artificial pancreas (six episodes) and control treatment (three episodes). Use of artificial pancreas was also associated with a reduction in overnight low blood glucose index (−0.37 (−0.56 to −0.18); 85%, 0.06, 11 studies).
Compared with control treatment, use of artificial pancreas had a favourable effect on mean levels of sensor blood glucose over 24 hours, which fell by 0.48 mmol/L (95% confidence interval 0.3 to 0.66; I 2 =84%, τ 2 =0.18, 32 studies; fig 6) . Results were more favourable for mean levels of sensor blood glucose overnight (overall weighted mean difference −0.81 mmol/L (−1.03 to −0.6); 78%, 0.3, 35 studies; appendix 10). These findings were consistent with the effect of artificial pancreas use on HbA 1c (−0.26% (−0.38% to −0.13%); 0%, 0.0, three studies; fig 7) . Finally, no difference between artificial pancreas use and control treatment was seen in the mean daily 
Sensitivity and subgroup analyses
Results for the proportion of time in near normoglycaemia were similar in a sensitivity analysis including only trials at low risk of bias, both over 24 hours (overall weighted mean difference 11.64% (95% confidence interval 9.1% to 14.18%); 10 studies) and overnight (20.18% (13.18% to 27.19%); five studies; fig 8 and fig 9) . Similarly, results for near normoglycaemia did not differ in a series of sensitivity analyses excluding trials that using artificial pancreas in diabetes camps or including only trials using artificial pancreas in unsupervised patients in normal living conditions. This similarity was seen both for the 24 hour period (10.42% (95% confidence interval 8.63% to 12.2%) and 10.67% (8.33% to 13.01%), respectively; appendices 13 and 14) and overnight period (13.47% (10.41% to 16.54%) and 15.53% (10.12% to 20.94%), respectively; appendices 15 and 16). We also did a post hoc sensitivity analysis excluding trials comparing artificial pancreas systems with low glucose suspend systems, to explore their effect on hypoglycaemia. Time when concentrations were lower than 3.9 mmol/L was shortened compared with control 
Small study effects
Both visually and formally, no evidence of small study effects was seen for the proportion of time in near normoglycaemia over 24 hours (P=0.129). However, evidence of small study effects was seen (P<0.001) for the proportion of time in near normoglycaemia overnight, and visual inspection of the contour enhanced funnel plot suggested that small negative studies were missing (appendix 19). Nevertheless, the adjusted meta-analytical estimate after use of the trim and fill method remained in favour of artificial pancreas use (weighted mean difference 10.39% (95% confidence interval 7.30% to 13.49%), P<0.001).
discussion
Key findings
Our data suggest that use of artificial pancreas is associated with almost two and a half additional hours in near normoglycaemia over a 24 hour period compared with control treatment, mainly due to its favourable effect during the overnight period. This finding was also verified by its effect on time in hyperglycaemia (two hours less than control treatment) and in hypoglycaemia (20 minutes less). Results were robust both for single and dual hormone systems, and were consistent in all sensitivity analyses performed-including an analysis restricted to trials under normal living conditions without remote monitoring, supporting the convenience and ease of use of artificial pancreas systems. Finally, this favourable effect was also evident in the relative reduction of mean blood glucose levels by 0.48 mmol/L, which is consistent with the HbA 1c reduction of about 0.3% recorded in trials with a duration of more than eight weeks per intervention. 44 63 64 Overall, our results reflect the progress made over recent decades of extensive research and development in artificial pancreas use. Comparison with other studies Despite heterogeneity in interventions and comparators used, our systematic review provides a valid and up to date overview on the use of artificial pancreas. An early pooled analysis of randomised controlled trials with artificial pancreas systems, published in 2011, included only four studies in an inpatient setting. 8 The effect of artificial pancreas in the outpatient setting was examined in a recent systematic review and meta-analysis of 24 randomised controlled trials (585 participants). 10 However, validity and clinical interpretation potential of the results were undermined by methodological decisions regarding the definition of outcomes, handling of median values, and exclusion of evidence from grey literature sources, potentially missing a substantial amount of evidence. 65 Our systematic review and meta-analysis incorporated a much larger pool of eligible studies (n=41) and participants (n=1042) and assessed a broader variety of outcomes, focusing on outcome definitions considered most important in trials evaluating artificial pancreas systems. [66] [67] [68] Furthermore, Weisman and colleagues analysed only 24 hour outcomes for studies investigating artificial pancreas use for 24 hour periods and analysed only overnight outcomes for studies investigating artificial pancreas use overnight, even when individual trials provided data for both periods. 10 Instead, our systematic review dealt with the research question 
Overnight use of arti cial pancreas
Strengths and limitations of study
Composition of the review team ensured appropriate methodological and field expertise, but also access to additional study data from individual studies. 41 45 60-63 To ensure internal validity of our conclusions, we implemented current guidelines for the conduct and reporting of systematic reviews, 12 and adhered to a prespecified protocol with minimal deviations. We undertook a comprehensive search of multiple databases without imposing any restrictions based on language or publication type, and assessed quality of trials using valid methodological tools. Moreover, we synthesised existing data using appropriate methodology to account for inappropriate reporting and analysis methods used in some of the trials . ( . to . )
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Favours arti cial pancreas included. In addition, we conducted a range of sensitivity analyses excluding trials using remote monitoring or trials at high risk of bias, to examine clinical relevance and robustness of our findings. We acknowledge several limitations at the evidence and review level. Most trials had a small sample size, limiting the precision of our effect estimates. Despite using broad inclusion criteria, existing studies provided limited insight regarding clinically relevant subgroups, such as those with increased hypoglycaemia burden, hypoglycaemia unawareness, gastroparesis, blindness, high HbA 1c , treated with corticosteroids, or from ethnic minorities. 69 Many trials were at high or unclear risk of bias owing to suboptimal reporting. Specifically, most trials reported effect estimates for outcomes related to hypoglycaemia using median values and interquartile ranges, thus we had to impute mean and standard deviation values for the meta-analyses. In addition, several crossover trials reported results as parallel group studies, [47] [48] [49] which also required use of imputation methods to allow synthesis of results.
Furthermore, we did not register our protocol at a publicly available database, and submitted it only for internal peer review. We focused on surrogate outcomes and did not extract evidence for specific patient outcomes such as quality of life, incidence of ketoacidosis, or catheter occlusion. Instead, we adopted a practical approach focusing on outcomes that we expected to be most and best reported in trials. 68 Moreover, for missing or inappropriately reported data, we refrained from contacting study authors other than those who were members of the review group, but used appropriate methodology to impute data. 70 Finally, most analyses had a high degree of heterogeneity, which could be attributed to differences in continuous glucose monitoring used, sensor accuracy and performance, compliance with artificial pancreas use in supervised and unsupervised settings, and comparators used during control treatment if sensor glucose readings were or were not available.
These differences could explain wide prediction intervals that included zero values for most outcomes in trials using artificial pancreas over 24 hours; thus, related findings should be interpreted with caution. By contrast, strong evidence indicated that overnight use of artificial pancreas would be beneficial for outcomes regarding time in near normoglycaemia, hyperglycaemia, or hypoglycaemia (95% prediction intervals excluding zero values), suggesting that this treatment effect can be expected in future patients.
Implications
Our study highlights some pitfalls in the conduct and reporting of artificial pancreas trials. Many trials had a short duration or were designed to assess the feasibility or safety, rather than long term effectiveness. Despite existing guidance, we noted significant variation in outcomes assessed and metrics used. 71 Research groups should report a minimum set of agreed outcome measures and respective metrics. [66] [67] [68] To ensure the clinical relevance and feasibility of this core outcome set, it is crucial that its development involves all key stakeholders, including patients, their families, clinicians, researchers, statisticians, methodologists, industry representatives, regulatory authorities, and funders.
To maximise the yield of information and to facilitate analysis and synthesis of evidence overall, the use of a common repository for data on individual patients could be agreed on. 72 73 Such repositories would facilitate free dissemination of raw trial data, allowing for replication of previous research findings using various analysis approaches (for example, a repeated measures analysis) of clinically relevant outcomes. Moreover, to enhance the external validity of evidence, future trials should broaden inclusion criteria and recruit more heterogeneous populations, including ethnic minorities.
The performance of current artificial pancreas systems could be enhanced by the optimisation of system components. Use of novel insulin analogues with faster pharmacokinetics, 74 the development of glucagon preparation stable at room temperature, and integration of artificial pancreas components into one device could further enhance user experience and artificial pancreas usefulness, and thus increase uptake. Future research should explore the potential differences between individual components (algorithms, continuous glucose monitoring) and determine their clinical relevance.
Upcoming trials should clarify the differences between single hormone and dual hormone systems, and explore artificial pancreas use in relevant groups of people with type 2 diabetes such as those with inpatient hyperglycaemia. 75 Moreover, the effect of artificial pancreas use on quality of life and on reducing patient burden should be further explored, 76 considering that patients with type 1 diabetes and their carers have shown a positive attitude towards artificial pancreas systems. [77] [78] [79] Finally, to support adoption, cost effectiveness should be assessed to allow for reimbursement by various healthcare systems, and ensure that adequate infrastructure exists.
Conclusions
Our systematic review and meta-analysis has shown that artificial pancreas systems are an efficacious and safe treatment approach for people with type 1 diabetes, leading to increased time in near normoglycaemic range, and reduced time in hypoglycaemia and hyperglycaemia. The results were verified for all types of artificial pancreas and in all sensitivity analyses. Further research with rigorous studies, cooperation of research groups in terms of outcome reporting, and cost effectiveness data are required to verify these findings and support adoption of artificial pancreas systems in clinical practice.
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